Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / BPC-157
Not FDA-approvedInsufficient
BPC-157
ALSO KNOWN ASBody protection compound 157
A heavily marketed repair peptide whose human evidence does not support the confidence of the claims.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed as injectable, oral, nasal and topical products; none is approved
04DOSE BASISReported clinic use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What BPC-157 is.
A synthetic 15-amino-acid peptide derived from a sequence described in gastric juice research. Most tendon, ligament, gut and wound-healing claims trace to cell or animal models rather than controlled human trials.
HOW IT IS THOUGHT TO WORK
Proposed effects involve angiogenesis, nitric-oxide signaling, inflammation and tissue repair, but the relevance and safety of these pathways in humans remain uncertain.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established clinical benefit for tendon, ligament, muscle or gut healing
- Preclinical findings have generated hypotheses, not a validated treatment
- Faster sports-injury recovery
- Healing of tendons or ligaments in humans
- Safe treatment of inflammatory bowel disease
- A safe oral or injectable dose
Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Reported clinic useMost commonly reported U.S. clinic range: 250–500 mcg total daily by subcutaneous injection, given once daily or divided, often for 4–8 weeks. This is a market-practice range—not an FDA-approved or validated guideline—and FDA's 2026 review found no human subcutaneous studies.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Clinic protocols commonly report 4–8 weeks, followed by reassessment. There is no validated course length, loading phase, taper or maintenance schedule.
- How to interpret it
- Men and women are generally described with the same reported range because no human evidence establishes a sex-based dose difference. Body size, indication, route, concentration, pregnancy potential, comorbidities and concurrent medicines still require individual review. Always confirm the exact order with the prescribing clinician and dispensing pharmacy.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Subcutaneous: FDA identified no human studies using the proposed subcutaneous route as of its May 2026 review.
- Intra-articular: 2–4 mg in one or two injections in a retrospective knee-pain series (17 identified patients).
- Intravesical: 10 mg in one procedure in a single-arm interstitial-cystitis study (12 women).
- Intravenous: 10 mg on day 1 and 20 mg on day 2 in a pilot involving two healthy adults.
- Rectal: up to 2 mg/kg daily for eight days in healthy volunteers and 80 mg daily for two weeks in a small ulcerative-colitis study.
- Oral: a phase 1 trial planned 1, 3 or 6 mg single doses and 3 mg every eight hours for two weeks, but no results were posted.
- Route
- Marketed as injectable, oral, nasal and topical products; none is approved
- Duration
- Clinic practice commonly reports 4–8 weeks; no course has been clinically validated
- Men & women
- The reported 250–500 mcg/day clinic range is generally the same for men and women. No human evidence establishes a sex-based adjustment, and reproductive safety data are inadequate.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- There is no validated lab panel that establishes safety
- A sports injury still requires diagnosis, load management and rehabilitation
SAFETY
Risks, red flags and reasons to avoid it.
- Unknown human toxicity and reproductive effects
- Immunogenicity, aggregation and peptide-related impurities
- Contamination, incorrect identity and dosing error
- Theoretical concern when manipulating angiogenic pathways
- Self-injection
- Pregnancy or fertility treatment
- Active cancer
- Using it to delay evaluation of a serious injury or GI disease
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
01
FDA evidence reviewFDA 2026 BPC-157 briefing document
↗02Peer-reviewed review2026 orthopaedic peptide evidence review
↗03Human pilotHuman IV pilot: 10 mg then 20 mg in two adults
↗04Market practice — not guidelineExample clinic-reported 250–500 mcg practice range
↗05FDA safetyFDA peptide compounding safety risks
↗PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Sold online and by some clinics despite no FDA-approved BPC-157 drug. FDA has proposed not adding BPC-157 substances to the 503A bulks list after reviewing limited evidence and safety concerns.
BPC-157 is a prime example of marketing moving faster than human evidence. Testimonials cannot establish purity, dose, healing or long-term safety.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP